We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+30.88%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$149M
AUM Growth
+$1.61M
Cap. Flow
+$7.75M
Cap. Flow %
5.19%
Top 10 Hldgs %
54.08%
Holding
54
New
19
Increased
8
Reduced
16
Closed
8

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$7.23M
2
TSHA icon
Taysha Gene Therapies
TSHA
+$7.15M
3
REPL icon
Replimune Group
REPL
+$2.95M
4
HLVX
HilleVax
HLVX
+$2.92M
5
ALKS icon
Alkermes
ALKS
+$2.4M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.17M
2
ARGX icon
argenx
ARGX
+$4.9M
3
CLNN icon
Clene
CLNN
+$3.73M
4
GHRS icon
GH Research
GHRS
+$2.9M
5
TERN
Terns Pharmaceuticals
TERN
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 91.72%
2 Financials 0.33%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.77B
$1.88M 1.26%
+15,500
New +$1.75M
VSTM icon
27
Verastem
VSTM
$519M
$1.87M 1.25%
230,000
-70,000
-23% -$672K
REPL icon
28
CALL
Replimune Group
REPL
$1.08B
$1.77M 1.18%
+1,000
New +$19.6K
ETNB
29
CALL
DELISTED
89bio
ETNB
$1.52M 1.02%
+1,000
New +$16.8K
ELVN icon
30
Enliven Therapeutics
ELVN
$4.31B
$1.42M 0.95%
103,600
-900
-0.9% -$15.2K
DYN icon
31
Dyne Therapeutics
DYN
$4.83B
$1.31M 0.88%
146,500
+73,500
+101% +$792K
KRON
32
DELISTED
Kronos Bio
KRON
$934K 0.63%
718,739
+403,739
+128% +$652K
ACRS icon
33
Aclaris Therapeutics
ACRS
$851M
$834K 0.56%
121,692
– –
BCLI
34
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$825K 0.55%
+167
New +$3.8K
BMEA icon
35
Biomea Fusion
BMEA
$90.4M
$550K 0.37%
39,935
-65
-0.2% -$1.17K
IONS icon
36
Ionis Pharmaceuticals
IONS
$9.06B
$513K 0.34%
+11,300
New +$466K
ETNB
37
DELISTED
89bio
ETNB
$506K 0.34%
+32,800
New +$551K
CYPH
38
Cypherpunk Technologies Inc
CYPH
$71.7M
$489K 0.33%
+354,166
New +$823K
RZLT icon
39
Rezolute
RZLT
$453M
$409K 0.27%
310,000
-63,400
-17% -$103K
CLRB icon
40
Cellectar Biosciences
CLRB
$20.1M
$320K 0.21%
+4,043
New +$238K
GPCR icon
41
Structure Therapeutics
GPCR
$3.74B
$252K 0.17%
+5,000
New +$161K
ANTX icon
42
AN2 Therapeutics
ANTX
$219M
$214K 0.14%
+13,300
New +$151K
MRNS
43
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$157K 0.11%
+19,500
New +$162K
MRSN
44
DELISTED
Mersana Therapeutics
MRSN
$127K 0.08%
+3,984
New +$189K
CBIO
45
Crescent Biopharma
CBIO
$610M
$41.3K 0.03%
+275
New +$43.4K
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$9.08K 0.01%
90,832
– –
ARGX icon
47
argenx
ARGX
$54.8B
– –
-12,568
Closed -$4.9M
ARWR icon
48
Arrowhead Research
ARWR
$12.1B
– –
-27,500
Closed -$981K
CLNN icon
49
Clene
CLNN
$68.2M
– –
-212,042
Closed -$3.73M
GHRS icon
50
GH Research
GHRS
$2.1B
– –
-244,828
Closed -$2.9M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Acuta Capital Partners held 54 positions worth $149M, up 1.1% from $148M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Acuta Capital Partners deployed $7.75M of net new capital in Q3 2023, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was RayzeBio, Inc. Common Stock: 344,571 shares worth $7.65M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 97% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.63M trimmed.

  • Acuta Capital Partners's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 344,571 shares worth $7.65M.
  • Acuta Capital Partners added most to HilleVax in Q3 2023, an estimated $2.92M increase.
  • Acuta Capital Partners's biggest Q3 2023 reduction was Terns Pharmaceuticals, cutting an estimated $2.63M.
  • Acuta Capital Partners fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $5.17M.
  • Acuta Capital Partners's ten largest holdings make up 54% of its $149M portfolio in Q3 2023.
  • Acuta Capital Partners opened 19 new positions and closed 8 in Q3 2023.
  • Acuta Capital Partners's portfolio value rose 1.1% quarter-over-quarter to $149M.

Based on Acuta Capital Partners's 13F filing for Q3 2023, filed 14 Nov 2023.